Treating Cancer with Novel Synthetic Lethal Therapies

Mini-library Approach Delivers an Arsenal in Drug Development Pipeline

Anticancer Bioscience appoints Dr. Hong Liu, as US-based VP of clinical development

ACB hires Liu from Eureka Therapeutics to lead push into clinic

Anticancer Bioscience: applying synthetic lethality to MYC-driven cancers

Dun Yang – President & CEO, Anticancer Bioscience

Synthetic lethal drugs vs. cancer

Anticancer Bioscience Raises $10M to Advance Synthetic Lethality Programs

China’s Anticancer Bioscience raises $10 million, aims high in China

Anticancer Bioscience announces $10 million financing

A synthetic lethality player emerges in China, armed with lessons on undruggable oncogene from Nobel laureate's lab